EP 2104R
Latest Information Update: 22 Apr 2010
At a glance
- Originator Dyax; EPIX Pharmaceuticals
- Developer EPIX Pharmaceuticals
- Class Contrast media; Lanthanoid series elements; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 20 Apr 2010 Intellectual properties pertaining to EP 2104R are being auctioned in the US (http://www.finnwarnkegayton.com)
- 07 Dec 2006 Final results from a phase IIA clinical trial in Magnetic resonance imaging added to the Diagnostic Agents therapeutic trials section
- 18 Jul 2006 EP 2104R is available for licensing worldwide (http://www.epixpharma.com)